HumanFirst

So proud to share that today, ICON plc launched Outcome Measures, a collection of end to end capabilities to support sponsors in conducting more patient-centered clinical trials. Key components within this suite of capabilities are: - Atlas, the most comprehensive platform?for the selection and deployment of digital measures throughout the trial lifecycle - ePROVIDE, the most extensive collection of COAs from Mapi Research Trust - eCOA + language translation services for COAs If you're conducting a clinical trial,?contact us to learn more about?this new offering! https://lnkd.in/gtnACxMk #clinicaltrials #patientinnovation

Thank you to all who came out for our panel session at #DIA2024 -- It was a great discussion, and we're excited about this next chapter where we'll work closely with Mapi Research Trust to build out an endpoint selection framework that can help researchers with more efficient protocol design. #clinicaltrials #patientoutcomes Roya Sherafat-Kazemzadeh (MD, PhD) Caprice Sassano

How did an earlier stage startup like HumanFirst find success, despite being in a highly regulated industry dominated by established, large organizations? A big contributing factor was how our CX team, led by Abby DeVito, built a toolkit of problem solving, relationship building, and storytelling. Read on for how this toolkit influenced HumanFirst's go-to-market approach, product strategy, and ultimately, helped lead us to an acquisition by ICON plc. https://lnkd.in/guhitS_Z #customerexperience #digitalbiomarkers #startups

#DIA2024 is around the corner, and we're looking forward to it! If you're attending, stop by our forum on June 19 at 8am PT to learn how a new framework to identify and compare biomarkers across both actively collected & passively-monitored COAs can enable rapid, evidence-based, and fit-for-purpose measures selection for clinical research. Moderated by Caprice Sassano and including speakers Roya Sherafat-Kazemzadeh (MD, PhD) Megan Parisi, MS, CCRP and Thomas Switzer, this forum will build off of our recent paper in Nature Magazine's npj Digital Medicine : https://lnkd.in/eQG9PGWG #DHT #COAs #clinicalresearch

"[I'm] inspired by HumanFirst and all the companies trying to make drug development more efficient, leading to better drugs to market, faster...we have to continue to invest [to] make clinical trials more inclusive and less burdensome on patients and sponsors." Thank you for sharing these important words Chloe Yoo, and thank you to Decent for highlighting Chloe's work at HumanFirst, now part of ICON plc. Read the full interview at the link in comments ??

As the use of wearable sensors increases across age and income brackets, pharmaceutical sponsors are increasingly leveraging digital biomarkers?and digital endpoints in trial protocols. HumanFirst's Head of Go to Market?Abby DeVito?shares learnings and insights on the?evolving landscape of digital biomarkers from?the recent Regeneron Digital Biomarker Summit. Read more of her takeaways:?https://lnkd.in/gAtTdiE5 #clinicaltrials #digitalhealth #patientoutcomes

We are very proud to share that HumanFirst has won the MedTech Breakthrough award. Congratulations to the whole team! We are thrilled to work in close collaboration with you to improve the lives of humans by accelerating the use of measures that matter in clinical trials.

Thrilled to be named the Best Clinical Trial Technology Solution Provider by MedTech Breakthrough! We are so excited to continue helping researchers build effective trials with patient-centric measures and innovative health technologies.?

Today is the day! Stop by to hear Andrea Coravos and Ida Sim?talk about the future of wearables in medicine at the #STATBreakthrough?Summit.

We're hiring at ICON/MAPI Research Trust! If you are passionate about COAs and digital health technologies, this role is for you. Come join us to shape the future of patient focused protocol design in clinical trials. https://lnkd.in/eGzMdTdX